nach oben

Current Heart Failure Reports

Erschienen in:

26.06.2019 | Updates in Advanced Heart Failure (E. Rame and M. St. John Sutton, Section Editors)

From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies

verfasst von: Nosheen Reza, Kiran Musunuru, Anjali Tiku Owens

Erschienen in: Current Heart Failure Reports | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this review is to provide an update on the recent advances in the research and clinical care of patients with the major phenotypes of inherited cardiomyopathies—hypertrophic, dilated, and arrhythmogenic. Developments in genetics, risk stratification, therapies, and disease modeling will be discussed.

Recent

Diagnostic, prognostic, and therapeutic tools which incorporate genetic and genomic data are being steadily incorporated into the routine clinical care of patients with genetic cardiomyopathies. Human pluripotent stem cells are a breakthrough model system for the study of genetic variation associated with inherited cardiovascular disease.

Summary

Next-generation sequencing technology and molecular-based diagnostics and therapeutics have emerged as valuable tools to improve the recognition and care of patients with hypertrophic, dilated, and arrhythmogenic cardiomyopathies. Improved adjudication of variant pathogenicity and management of genotype-positive/phenotype-negative individuals are imminent challenges in this realm of precision medicine.

Goodwin JF, Gordon H, Hollman A, Bishop MB. Clinical aspects of cardiomyopathy. Br Med J. 1961;1(5219):69–79.PubMedPubMedCentral

Fontaine G, Guiraudon G, Frank R, Vedel J, Grosgogeat Y, Cabrol C, et al. Stimulation studies and epicardial mapping in ventricular tachycardia: study of mechanisms and selection for surgery. In: Re-entrant arrhythmias: mechanisms and treatment. Baltimore: University Park Press; 1977.

Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65(2):384–98.PubMed

Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807–16. https://doi.org/10.1161/circulationaha.106.174287.CrossRefPubMed

Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J. 2008;29(2):270–6. https://doi.org/10.1093/eurheartj/ehm342.CrossRefPubMed

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76. https://doi.org/10.1016/j.cell.2006.07.024.CrossRefPubMed

Musunuru K, Sheikh F, Gupta RM, Houser SR, Maher KO, Milan DJ, et al. Induced pluripotent stem cells for cardiovascular disease modeling and precision medicine: a scientific statement from the American Heart Association. Circ Genom Precision Med. 2018;11(1):e000043. https://doi.org/10.1161/hcg.0000000000000043.CrossRef

Matsa E, Ahrens JH, Wu JC. Human induced pluripotent stem cells as a platform for personalized and precision cardiovascular medicine. Physiol Rev. 2016;96(3):1093–126. https://doi.org/10.1152/physrev.00036.2015.CrossRefPubMedPubMedCentral

Cirino AL, Lakdawala NK, McDonough B, Conner L, Adler D, Weinfeld M, et al. A comparison of whole genome sequencing to multigene panel testing in hypertrophic cardiomyopathy patients. Circ Cardiovasc Genet. 2017;10(5):e001768. https://doi.org/10.1161/circgenetics.117.001768.CrossRefPubMedPubMedCentral

10.

• Bagnall RD, Ingles J, Dinger ME, Cowley MJ, Ross SB, Minoche AE, et al. Whole genome sequencing improves outcomes of genetic testing in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2018;72(4):419–29. https://doi.org/10.1016/j.jacc.2018.04.078 This study demonstrates the utility of whole genome sequencing to identify causes of HCM in cases that were not diagnosed with targeted testing. CrossRefPubMed

11.

Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mechanistic insights into the genetics of Cardiomyopathy. J Am Coll Cardiol. 2016;68(25):2871–86. https://doi.org/10.1016/j.jacc.2016.08.079.CrossRefPubMedPubMedCentral

12.

Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212–60. https://doi.org/10.1016/j.jacc.2011.06.011.CrossRefPubMed

13.

Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79. https://doi.org/10.1093/eurheartj/ehu284.CrossRefPubMed

14.

Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation. 1995;92(4):785–9.PubMed

15.

Hada Y, Sakamoto T, Amano K, Yamaguchi T, Takenaka K, Takahashi H, et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol. 1987;59(1):183–4.PubMed

16.

Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 2004;116(1):14–8.PubMed

17.

Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol. 1999;33(6):1590–5.PubMed

18.

Maron BJ, Spirito P, Roman MJ, Paranicas M, Okin PM, Best LG, et al. Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). Am J Cardiol. 2004;93(12):1510–4.PubMed

19.

Maro E, Janabi M, Kaushik R. Clinical and echocardiographic study of hypertrophic cardiomyopathy in Tanzania. Trop Dr. 2006;36(4):225–7.

20.

Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249–54.PubMed

21.

Millat G, Bouvagnet P, Chevalier P, Dauphin C, Jouk PS, Da Costa A, et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet. 2010;53(5):261–7.PubMed

22.

Kaski JP, Syrris P, Esteban MTT, Jenkins S, Pantazis A, Deanfield JE, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ: Genom Precision Med. 2009;2(5):436–41.

23.

Erdmann J, Daehmlow S, Wischke S, Senyuva M, Werner U, Raible J, et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet. 2003;64(4):339–49.PubMed

24.

Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107(17):2227–32.PubMed

25.

Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'donoghue A, et al. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332(16):1058–65.PubMed

26.

Kimura A, Harada H, Park JE, Nishi H, Satoh M, Takahashi M, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet. 1997;16(4):379–82.PubMed

27.

Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg H-P, et al. α-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994;77(5):701–12.PubMed

28.

Mogensen J, Klausen IC, Pedersen AK, Egeblad H, Bross P, Kruse TA, et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest. 1999;103(10):R39–43. https://doi.org/10.1172/jci6460. CrossRefPubMedPubMedCentral

29.

Olson TM, Doan TP, Kishimoto NY, Whitby FG, Ackerman MJ, Fananapazir L. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2000;32(9):1687–94. https://doi.org/10.1006/jmcc.2000.1204.CrossRefPubMed

30.

Poetter K, Jiang H, Hassanzadeh S, Master SR, Chang A, Dalakas MC, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet. 1996;13(1):63–9. https://doi.org/10.1038/ng0596-63.CrossRefPubMed

31.

Geier C, Gehmlich K, Ehler E, Hassfeld S, Perrot A, Hayess K, et al. Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. Hum Mol Genet. 2008;17(18):2753–65.PubMed

32.

Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749–70. https://doi.org/10.1161/circresaha.117.311059.CrossRefPubMedPubMedCentral

33.

Marian AJ. The case of “missing causal genes” and the practice of medicine: a Sherlock Holmes approach of deductive reasoning. Circ Res. 2016;119(1):21–4.PubMedPubMedCentral

34.

Li L, Bainbridge MN, Tan Y, Willerson JT, Marian AJ. A potential oligogenic etiology of hypertrophic cardiomyopathy: a classic single-gene disorder. Circ Res. 2017;120(7):1084–90.PubMedPubMedCentral

35.

Nistri S, Olivotto I, Maron MS, Ferrantini C, Coppini R, Grifoni C, et al. Beta blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012;110(5):715–9. https://doi.org/10.1016/j.amjcard.2012.04.051.CrossRefPubMed

36.

Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251–8. https://doi.org/10.1016/j.jacc.2005.01.012.CrossRefPubMed

37.

Gilligan DM, Chan WL, Joshi J, Clarke P, Fletcher A, Krikler S, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;21(7):1672–9.PubMed

38.

Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA, et al. Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J Am Coll Cardiol. 2015;66(11):1307–8. https://doi.org/10.1016/j.jacc.2015.06.1333.CrossRefPubMed

39.

Maron BJ, Nishimura RA. Surgical septal myectomy versus alcohol septal ablation: assessing the status of the controversy in 2014. Circulation. 2014;130(18):1617–24. https://doi.org/10.1161/circulationaha.114.011580.CrossRefPubMed

40.

Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003-2011. JAMA Cardiol. 2016;1(3):324–32. https://doi.org/10.1001/jamacardio.2016.0252.CrossRefPubMed

41.

Patel SR, Saeed O, Naftel D, Myers S, Kirklin J, Jorde UP, et al. Outcomes of restrictive and hypertrophic cardiomyopathies after LVAD: an INTERMACS analysis. J Card Fail. 2017;23(12):859–67. https://doi.org/10.1016/j.cardfail.2017.09.011.CrossRefPubMed

42.

Maron MS, Kalsmith BM, Udelson JE, Li W, DeNofrio D. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3(5):574–9. https://doi.org/10.1161/circheartfailure.109.922872.CrossRefPubMed

43.

Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, et al. Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2018;121(8):986–96.PubMed

44.

O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35(30):2010–20. https://doi.org/10.1093/eurheartj/eht439.CrossRefPubMed

45.

Vriesendorp PA, Schinkel AF, Liebregts M, Theuns DA, van Cleemput J, ten Cate FJ, et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8(4):829–35.PubMed

46.

Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol. 2015;116(5):757–64.PubMed

47.

Fernández A, Quiroga A, Ochoa JP, Mysuta M, Casabé JH, Biagetti M, et al. Validation of the 2014 European Society of Cardiology sudden cardiac death risk prediction model in hypertrophic cardiomyopathy in a reference center in South America. Am J Cardiol. 2016;118(1):121–6.PubMed

48.

Ruiz-Salas A, García-Pinilla J, Cabrera-Bueno F, Fernández-Pastor J, Peña-Hernández J, Medina-Palomo C, et al. Comparison of the new risk prediction model (HCM risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator. Europace. 2016;18(5):773.PubMed

49.

O'Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM). Circulation. 2018;137(10):1015–23. https://doi.org/10.1161/circulationaha.117.030437.CrossRefPubMed

50.

Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484–95.PubMed

51.

Mentias A, Raeisi-Giglou P, Smedira NG, Feng K, Sato K, Wazni O, et al. Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol. 2018;72(8):857–70.PubMed

52.

• Kramer CM, Appelbaum E, Desai MY, Desvigne-Nickens P, JP DM, Friedrich MG, et al. Hypertrophic cardiomyopathy registry: the rationale and design of an international, observational study of hypertrophic cardiomyopathy. Am Heart J. 2015;170(2):223–30 This article reviews the design of the highly anticipated international Hypertrophic Cardiomyopathy Registry.PubMedPubMedCentral

53.

van Velzen HG, Vriesendorp PA, Oldenburg RA, van Slegtenhorst MA, van der Velden J, Schinkel AF, et al. Value of genetic testing for the prediction of long-term outcome in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2016;118(6):881–7.PubMed

54.

Li Q, Gruner C, Chan RH, Care M, Siminovitch K, Williams L, et al. Genotype-positive status in patients with hypertrophic cardiomyopathy is associated with higher rates of heart failure events. Circ Cardiovasc Genet. 2014;7(4):416–22. https://doi.org/10.1161/circgenetics.113.000331.CrossRefPubMed

55.

Alfares AA, Kelly MA, McDermott G, Funke BH, Lebo MS, Baxter SB, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17:880–8. https://doi.org/10.1038/gim.2014.205.CrossRefPubMed

56.

Ho CY, McMurray JJ, Cirino AL, Colan SD, Day SM, Desai AS, et al. The design of the valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy (VANISH) trial. Am Heart J. 2017;187:145–55.PubMedPubMedCentral

57.

Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351(6273):617–21.PubMedPubMedCentral

58.

Jacoby D, Lester S, Owens A, Wang A, Young D, Tripuraneni R, et al. Reduction in left ventricular outflow tract gradient with mavacamten (MYK-461) in symptomatic obstructive hypertrophic patients (PIONEER-HCM). J Am Coll Cardiol. 2018;71(11 Supplement):A644. https://doi.org/10.1016/s0735-1097(18)31185-9.CrossRef

59.

Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013;12(1):101–13. https://doi.org/10.1016/j.stem.2012.10.010.CrossRefPubMedPubMedCentral

60.

Han L, Li Y, Tchao J, Kaplan AD, Lin B, Li Y, et al. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells. Cardiovasc Res. 2014;104(2):258–69. https://doi.org/10.1093/cvr/cvu205.CrossRefPubMedPubMedCentral

61.

Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report—2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36(10):1037–46.PubMed

62.

Sefa MO, Tuluce K, Yakar ST, Kilic S, Soner HK, Sayin A, et al. Screening first-degree relatives of patients with idiopathic dilated cardiomyopathy. Herz. 2017;42(7):669–76.

63.

Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134(23):e579–646.PubMed

64.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.PubMed

65.

Petretta M, Pirozzi F, Sasso L, Paglia A, Bonaduce D. Review and metaanalysis of the frequency of familial dilated cardiomyopathy. Am J Cardiol. 2011;108(8):1171–6.PubMed

66.

Mestroni L, Maisch B, McKenna W, Schwartz K, Charron P, Rocco C, et al. Guidelines for the study of familial dilated cardiomyopathies. Eur Heart J. 1999;20(2):93–102.PubMed

67.

Kinnamon DD, Morales A, Bowen DJ, Burke W, Hershberger RE. Toward genetics-driven early intervention in dilated cardiomyopathy: design and implementation of the DCM precision medicine study. Circ Cardiovasc Genet. 2017;10(6). https://doi.org/10.1161/circgenetics.117.001826.

68.

• Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2014;36(18):1123–35 This study is a comprehensive investigation of the genetics of DCM in a large-scale cohort. PubMed

69.

Ganesh SK, Arnett DK, Assimes TL, Basson CT, Chakravarti A, Ellinor PT, et al. Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association. Circulation. 2013;128(25):2813–51.PubMed

70.

Hershberger RE, Morales A. Dilated cardiomyopathy overview. In: GeneReviews [Internet]. University of Washington, Seattle, Seattle, Washington. 1993. https://www.ncbi.nlm.nih.gov/books/NBK1309/. Accessed 15 July 2018.

71.

Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10(9):531–47. https://doi.org/10.1038/nrcardio.2013.105 CrossRefPubMed

72.

Pugh TJ, Kelly MA, Gowrisankar S, Hynes E, Seidman MA, Baxter SM, et al. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med. 2014;16(8):601–8.PubMed

73.

Golbus JR, Puckelwartz MJ, Dellefave-Castillo L, Fahrenbach JP, Nelakuditi V, Pesce LL, et al. Targeted analysis of whole genome sequence data to diagnose genetic cardiomyopathy. Circ Genom Precis Med. 2014;7(6):751–9.

74.

Minoche AE, Horvat C, Johnson R, Gayevskiy V, Morton SU, Drew AP, et al. Genome sequencing as a first-line genetic test in familial dilated cardiomyopathy. Genet Med. 2018;21:650–62. https://doi.org/10.1038/s41436-018-0084-7.CrossRefPubMedPubMedCentral

75.

Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619–28. https://doi.org/10.1056/NEJMoa1110186.CrossRefPubMedPubMedCentral

76.

Roberts AM, Ware JS, Herman DS, Schafer S, Baksi J, Bick AG, et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med. 2015;7(270):270ra6-ra6. https://doi.org/10.1126/scitranslmed.3010134.CrossRef

77.

Akinrinade O, Koskenvuo JW, Alastalo T-P. Prevalence of titin truncating variants in general population. PLoS One. 2015;10(12):e0145284.PubMedPubMedCentral

78.

Norton N, Li D, Rampersaud E, Morales A, Martin ER, Zuchner S, et al. Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. Circ Cardiovasc Genet. 2013;6(2):144–53. https://doi.org/10.1161/circgenetics.111.000062.CrossRefPubMed

79.

Hinson JT, Chopra A, Nafissi N, Polacheck WJ, Benson CC, Swist S, et al. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. 2015;349(6251):982–6. https://doi.org/10.1126/science.aaa5458.CrossRefPubMedPubMedCentral

80.

Parks SB, Kushner JD, Nauman D, Burgess D, Ludwigsen S, Peterson A, et al. Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am Heart J. 2008;156(1):161–9.PubMedPubMedCentral

81.

van Tintelen JP, Hofstra RM, Katerberg H, Rossenbacker T, Wiesfeld AC, du Marchie Sarvaas GJ, et al. High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. Am Heart J. 2007;154(6):1130–9.PubMed

82.

Siu CW, Lee YK, Ho JC, Lai WH, Chan YC, Ng KM, et al. Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. Aging. 2012;4(11):803–22. https://doi.org/10.18632/aging.100503.CrossRefPubMedPubMedCentral

83.

Fatkin D, Macrae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999;341(23):1715–24.PubMed

84.

van Rijsingen IAW, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59(5):493–500. https://doi.org/10.1016/j.jacc.2011.08.078.CrossRefPubMed

85.

Meune C, Van Berlo JH, Anselme F, Bonne G, Pinto YM, Duboc D. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354(2):209–10.PubMed

86.

Anselme F, Moubarak G, Savouré A, Godin B, Borz B, Drouin-Garraud V, et al. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10(10):1492–8. https://doi.org/10.1016/j.hrthm.2013.06.020.CrossRefPubMed

87.

• Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal J-M, Androulakis AF, et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol. 2016;68(21):2299–307 This article contributes important natural history and prognostic information about LMNA -related heart disease.PubMed

88.

Kusumoto FM, Calkins H, Boehmer J, Buxton AE, Chung MK, Gold MR, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. J Am Coll Cardiol. 2014;64(11):1143–77. https://doi.org/10.1016/j.jacc.2014.04.008.CrossRefPubMed

89.

Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867. https://doi.org/10.1093/eurheartj/ehv316.CrossRefPubMed

90.

McNair WP, Sinagra G, Taylor MR, Di Lenarda A, Ferguson DA, Salcedo EE, et al. SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism. J Am Coll Cardiol. 2011;57(21):2160–8.PubMed

91.

Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent V, et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol. 2016;68(22):2440–51. https://doi.org/10.1016/j.jacc.2016.09.927.CrossRefPubMed

92.

Van Der Zwaag PA, Van Rijsingen IA, Asimaki A, Jongbloed JD, Van Veldhuisen DJ, Wiesfeld AC, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012;14(11):1199–207.PubMedPubMedCentral

93.

Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med. 2012;4(130):130ra47. https://doi.org/10.1126/scitranslmed.3003552.CrossRefPubMedPubMedCentral

94.

Karakikes I, Stillitano F, Nonnenmacher M, Tzimas C, Sanoudou D, Termglinchan V, et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun. 2015;6:6955. https://doi.org/10.1038/ncomms7955.CrossRefPubMed

95.

Tse HF, Ho JC, Choi SW, Lee YK, Butler AW, Ng KM, et al. Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing. Hum Mol Genet. 2013;22(7):1395–403. https://doi.org/10.1093/hmg/dds556.CrossRefPubMed

96.

Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature. 2013;494(7435):105–10. https://doi.org/10.1038/nature11799.CrossRefPubMedPubMedCentral

97.

Caspi O, Huber I, Gepstein A, Arbel G, Maizels L, Boulos M, et al. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. Circ Cardiovasc Genet. 2013;6(6):557–68. https://doi.org/10.1161/circgenetics.113.000188.CrossRefPubMed

98.

Ma D, Wei H, Lu J, Ho S, Zhang G, Sun X, et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2013;34(15):1122–33. https://doi.org/10.1093/eurheartj/ehs226.CrossRefPubMed

99.

Dick E, Kalra S, Anderson D, George V, Ritso M, Laval SH, et al. Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations. Stem Cells Dev. 2013;22(20):2714–24. https://doi.org/10.1089/scd.2013.0135.CrossRefPubMedPubMedCentral

100.

Lin B, Li Y, Han L, Kaplan AD, Ao Y, Kalra S, et al. Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy. Dis Model Mech. 2015;8(5):457–66. https://doi.org/10.1242/dmm.019505.CrossRefPubMedPubMedCentral

101.

Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med. 2014;20(6):616–23. https://doi.org/10.1038/nm.3545.CrossRefPubMedPubMedCentral

102.

Kodo K, Ong SG, Jahanbani F, Termglinchan V, Hirono K, Inanloo RK, et al. iPSC-derived cardiomyocytes reveal abnormal TGF-beta signalling in left ventricular non-compaction cardiomyopathy. Nat Cell Biol. 2016;18(10):1031–42. https://doi.org/10.1038/ncb3411.CrossRefPubMedPubMedCentral

103.

Ang YS, Rivas RN, Ribeiro AJS, Srivas R, Rivera J, Stone NR, et al. Disease model of GATA4 mutation reveals transcription factor cooperativity in human cardiogenesis. Cell. 2016;167(7):1734–49.e22. https://doi.org/10.1016/j.cell.2016.11.033.CrossRefPubMedPubMedCentral

104.

Tucker NR, McLellan MA, Hu D, Ye J, Parsons VA, Mills RW, et al. Novel mutation in FLNC (Filamin C) causes familial restrictive Cardiomyopathy. Circ Cardiovasc Genet. 2017;10(6). https://doi.org/10.1161/circgenetics.117.001780.

105.

Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy: dysplasia, dystrophy, or myocarditis? Circulation. 1996;94(5):983–91.PubMed

106.

Asimaki A, Saffitz JE. The role of endomyocardial biopsy in ARVC: looking beyond histology in search of new diagnostic markers. J Cardiovasc Electrophysiol. 2011;22(1):111–7.PubMed

107.

Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, Lopez-Cuenca D, Sanchez-Munoz JJ, Oliva-Sandoval MJ, et al. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2015;12(4):766–73.PubMed

108.

Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Eur Heart J. 2010;31(7):806–14. https://doi.org/10.1093/eurheartj/ehq025.CrossRefPubMedPubMedCentral

109.

Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52(25):2175–87.PubMed

110.

Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nature Genet. 2004;36(11):1162–4. https://doi.org/10.1038/ng1461.CrossRefPubMed

111.

Rampazzo A, Nava A, Malacrida S, Beffagna G, Bauce B, Rossi V, et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet. 2002;71(5):1200–6. https://doi.org/10.1086/344208.CrossRefPubMedPubMedCentral

112.

Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006;113(9):1171–9. https://doi.org/10.1161/circulationaha.105.583674.CrossRefPubMed

113.

Syrris P, Ward D, Evans A, Asimaki A, Gandjbakhch E, Sen-Chowdhry S, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet. 2006;79(5):978–84. https://doi.org/10.1086/509122.CrossRefPubMedPubMedCentral

114.

McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet. 2000;355(9221):2119–24. https://doi.org/10.1016/s0140-6736(00)02379-5.CrossRefPubMed

115.

• Gandjbakhch E, Redheuil A, Pousset F, Charron P, Frank R. Clinical diagnosis, imaging, and genetics of arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Am Coll Cardiol. 2018;72(7):784–804 This is an excellent review of ARVC/D by the group involved in its early description.PubMed

116.

Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017;376(1):61–72. https://doi.org/10.1056/NEJMra1509267.CrossRefPubMed

117.

Quarta G, Muir A, Pantazis A, Syrris P, Gehmlich K, Garcia-Pavia P, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy impact of genetics and revised task force criteria. Circulation. 2011;123(23):2701–U99. https://doi.org/10.1161/circulationaha.110.976936.CrossRefPubMed

118.

Groeneweg JA, Bhonsale A, James CA, te Riele AS, Dooijes D, Tichnell C, et al. Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet. 2015;8(3):437–46. https://doi.org/10.1161/circgenetics.114.001003.CrossRefPubMed

119.

Hodgkinson K, Connors S, Merner N, Haywood A, Young TL, McKenna W, et al. The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p. S358L mutation in TMEM43. Clin Genet. 2013;83(4):321–31.PubMed

120.

Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, Jongbloed JD, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J. 2015;36(14):847–55.PubMed

121.

James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy–associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62(14):1290–7.PubMed

122.

Xu TH, Yang Z, Vatta M, Rampazzo A, Beffagna G, Pillichou K, et al. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2010;55(6):587–97. https://doi.org/10.1016/j.jacc.2009.11.020.CrossRefPubMedPubMedCentral

123.

•• Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2. 0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19(2):249 This policy statement provides an update regarding the clinician's responsibility of reporting of secondary findings in clinical genetic sequencing.PubMed

Titel: From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies
verfasst von: Nosheen Reza
Kiran Musunuru
Anjali Tiku Owens
Publikationsdatum: 26.06.2019
Verlag: Springer US
Erschienen in: Current Heart Failure Reports / Ausgabe 5/2019
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-019-00435-0

Neu im Fachgebiet Kardiologie

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies

Abstract

Purpose

Recent

Summary

Neu im Fachgebiet Kardiologie

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Update Kardiologie

Springer Medizin

Abstract

Purpose

Recent

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Pulmonary Hypertension in Advanced Heart Failure: Assessment and Management of the Failing RV and LV

Introduction to Topical Collection on Updates in Advanced Heart Failure

Identifying Stage D Heart Failure: Data From the Most Recent Registries

Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis

Anabolism to Catabolism: Serologic Clues to Nutritional Status in Heart Failure

Updates on Heart Transplantation

Neu im Fachgebiet Kardiologie

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Update Kardiologie